Aeglea BioTherapeutics Inc

NASDAQ:AGLE   3:59:52 PM EDT
1.50
0.00 (0.00%)
Earnings Announcements

Aeglea Biotherapeutics Reports First Quarter 2022 Results

Published: 05/05/2022 12:04 GMT
Aeglea BioTherapeutics Inc (AGLE) - Aeglea Biotherapeutics Reports First Quarter 2022 Financial Results and Provides Program Updates.
Aeglea Bio Therapeutics Inc - Enrollment Continues in Phase 1/2 Trial of Agle-177; Ind Now Open for U.S. Site Initiation.
Aeglea Bio Therapeutics Inc Qtrly Loss per Share $0.37.
Aeglea Bio - Expects Cash, Cash Equivalents & Investments Will Enable It to Fund Its Operating Expenses & Capital Expenditure Into Q1 of 2023.
Revenue is expected to be $0.57 Million
Adjusted EPS is expected to be -$0.31

Next Quarter Revenue Guidance is expected to be $0.54 Million
Next Quarter EPS Guidance is expected to be -$0.31

More details on our Analysts Page.